Tempe activity and the nearest visit both affect your choice

Your usual route shows what the sore joint must handle

A route of about five miles circles Town Lake before joining the Rio Salado path. Tempe has more than 200 miles of bikeways within roughly 40 square miles. If you cycle to work or the store, resting affects more than exercise. Tell the clinic how far you ride, where hills start, and which motion hurts.

Court play adds fast stops and turns. The Tempe Sports Complex has sixteen free pickleball courts, while Kiwanis Park has fifteen tennis courts. An ache that grew slowly isn't the same as a pop followed by lost strength. A sudden pop and weakness need an exam before you return to play.

Name the exact motion that hurts.

Chandler is the direct clinic trip for much of Tempe

McClintock Road becomes Dobson Road after you cross into Chandler. From south Tempe, the Chandler medical corridor is about five miles away. From Central Tempe, the Chandler clinic is roughly nine miles away, often a 15 to 17 minute drive when traffic isn't busy. North Tempe can use Scottsdale Road or the Loop 101 toward Scottsdale. A sore leg can make even a short drive hard.

At 1100 S. Dobson Rd., Suite 210, Chandler, AZ 85286, QC Kinetix offers regenerative care, meaning non-surgical treatment prepared by separating your blood and placing the concentrated part near the sore joint. Medical providers are the clinic staff who examine you and give the care. The Scottsdale location is at 9220 E. Mountain View Rd., Suite 210. Ask what a visit includes and whether you'll need return trips. Call the Phoenix-area clinic team at (602) 837-PAIN.

Choose the trip you can manage.

Sources

1. The 2019 ACR/Arthritis Foundation osteoarthritis guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-management programmes, tai chi, cane use, tibiofemoral bracing, topical and oral NSAIDs and intra-articular glucocorticoid injections for knee OA. Its conditional recommendations cover balance exercises, yoga, CBT, acupuncture, thermal modalities, radiofrequency ablation, acetaminophen, duloxetine and tramadol. Anything offered before a course of the strongly recommended options is being offered out of order.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. The ESSKA-ICRS consensus applied the RAND/UCLA appropriateness method to 216 clinical scenarios for intra-articular PRP in knee OA. Only 84 scenarios (38.9%) were rated appropriate, 9 (4.2%) inappropriate and 123 (56.9%) uncertain. PRP was judged appropriate in patients aged 80 or under with KL grade 0-III osteoarthritis AFTER failed conservative non-injective or injective treatment; it was NOT considered appropriate as a first treatment, nor in KL grade IV (bone-on-bone) osteoarthritis, where 91.7% and 87.5% of scenarios respectively were uncertain.

   Kon E, de Girolamo L, Laver L, et al. — Platelet-rich plasma injections for the management of knee osteoarthritis: The ESSKA-ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenarios. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12320.

3. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for patients with chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development clinical study. There is no Medicare national coverage for PRP in osteoarthritis or tendinopathy, which is why these injections are billed to the patient as cash-pay.

   Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

4. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

   Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.

5. In a double-blind, placebo-controlled trial of 54 patients with chronic midportion Achilles tendinopathy, all doing eccentric exercises, VISA-A scores improved 21.7 points with PRP and 20.5 points with saline over 24 weeks - an adjusted between-group difference of -0.9 (95% CI -12.4 to 10.6), excluding the predefined relevant difference of 12 points. PRP added nothing to eccentric loading.

   de Vos RJ, Weir A, van Schie HT, et al. — Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA, 2010. DOI: 10.1001/jama.2009.1986.

6. A multicentre, double-blinded, placebo-controlled trial randomised 100 patients with ankle (tibiotalar) osteoarthritis to two ultrasound-guided intra-articular injections of PRP or placebo. Symptom scores improved by 10 points with PRP and 11 points with placebo, an adjusted between-group difference over 26 weeks of -1 (95% CI -6 to 3; P=.56). The authors concluded the results do not support the use of PRP injections for ankle osteoarthritis.

   Paget LDA, Reurink G, de Vos RJ, et al. — Effect of Platelet-Rich Plasma Injections vs Placebo on Ankle Symptoms and Function in Patients With Ankle Osteoarthritis: A Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.16602.

7. The devices used to spin PRP at the point of care are cleared by FDA as clinical centrifuges, product code JQC, a Class I device under 21 CFR 862.2050 - for example the Biomet GPS Platelet Separation Kit (K030555, cleared 2003) and the Harvest SmartPrep2 / SmartPrep Platelet Concentration System (K103340, cleared 2010). That clearance covers the equipment that separates blood. It is not an FDA approval of platelet-rich plasma as a treatment for osteoarthritis, tendinopathy or any other orthopedic condition, and copy must never blur the two.

   U.S. Food and Drug Administration (Center for Devices and Radiological Health) — 510(k) Premarket Notification database and Product Classification: JQC, Centrifuges (Micro, Ultra, Refrigerated) For Clinical Use, 21 CFR 862.2050. FDA accessdata (CDRH device databases), 2003.